Enanta Pharmaceuticals, Inc. announced that the first patient had been dosed in RESOLVE, its global Phase 2b/3 clinical trial of zelicapavir in adults at high risk of severe outcomes from RSV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results